Adjuvant Systemic Therapy in Node-Negative Breast Cancer

  • Manfred Kaufmann
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)

Abstract

After more than 40 years of experience with systemic adjuvant therapy and more than 100 reported randomised adjuvant trials in breast cancer, it can be stated that adjuvant treatment significantly changes the natural course of this systemic and chronic disease.

Keywords

Toxicity Osteoporosis Oncol Methotrexate Tamoxifen 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Early Breast Cancer Trialists Collaborative Group: The effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: An overview of 61 randomized trials among 28,896 women. N Engl J Med 1988 (319):1681–1692CrossRefGoogle Scholar
  2. 2.
    Glick JH: Closing summary and outlook. In: Senn HJ, Goldhirsch A, Gelber RD, Osterwalder B (eds): Adjuvant Therapy of Primary Breast Cancer. Recent Results in Cancer Research. Springer, Berlin 1989 pp 283–292Google Scholar
  3. 3.
    Bonadonna G: Conceptual and practical advances in the management of breast cancer: The 20th Annual Karnofsky Award Lecture. J Clin Oncol 1989 (10):1380–1397Google Scholar
  4. 4.
    Henderson IC: Adjuvant systemic therapy: State of the art, 1989. 11th San Antonio Breast Cancer Symposium Lecture. Breast Cancer Res Treatm 1989 (14):3–22CrossRefGoogle Scholar
  5. 5.
    Fisher B, Redmond C, Dimitrov NV et al: A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989 (320):473 478PubMedGoogle Scholar
  6. 6.
    Mansour EG, Gray R, Shatila AH et al: Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: an intergroup study. N Engl J Med. 1989 (320):485–490PubMedCrossRefGoogle Scholar
  7. 7.
    Ludwig Breast Cancer Study Group: Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for nodenegative breast cancer. N Engl J Med 1989 (320): 491–496CrossRefGoogle Scholar
  8. 8.
    Fisher B, Constantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989 (320):479–484PubMedCrossRefGoogle Scholar
  9. 9.
    Bryant AJ, Weir JA: Prophylactic oophorectomy in operable instances of carcinoma of the breast. Surg Gynecol Obstet 1981 (153):660–664PubMedGoogle Scholar
  10. 10.
    Cole MP: Prophylactic compared with therapeutic x- ray artifical menopause. 2nd Tenovus Workshop of Breast Cancer, 1970 pp 2–11Google Scholar
  11. 11.
    Ravdin RG, Lewison EF, Slack NH et al: Results of a clinical trial concerning the worth of prophylactic oophorectomy for breast carcinoma. Surg Gynecol Obstet 1970(31):1055–1064Google Scholar
  12. 12.
    Kaufmann M, Jonat W, Abel U: Adjuvant chemo and endocrine therapy alone or in combination in premenopausal patients (GABG Trial I). In: Senn HJ, Goldhirsch A, Gelber RD, Osterwalder B (eds): Adjuvant Therapy of Primary Breast Cancer. Recent Results in Cancer Research. Springer, Berlin 1989 pp 118–125Google Scholar
  13. 13.
    Meakin JW, Allt WEC, Beale FA et al: Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Breast Cancer Res Treat 1983 (3 supp):45–48Google Scholar
  14. 14.
    Meakin JW, Allt WEC, Beale FA et al: Ovarian irradiation and prednisone therapy following surgery and radiotherapy for carcinoma of the breast. Can Med Assoc J 1979 (120):1221–1228PubMedGoogle Scholar
  15. 15.
    Kaufmann M, Jonat W, Kleeberg U, Eiermann W, Jänicke F, Hilfrich J, Kreienberg R, Albrecht M, Weitzel HK, Schmid H, Strunz P, Schachner Wünschmann E, Bastert G, Maass H, for the German Zoladex Trial Group: Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer: J Clin Oncol 1989 (7):1113–1119PubMedGoogle Scholar
  16. 16.
    Kiesel L, Kaufmann M, Haeseler F, Klinga K, von Hoist T, Schmidt W, Runnebaum B: GnRH Rezeptoren im menschlichen Mammakarzinomgewebe: Geburts u Frauenheilk 1988 (48): 420–424CrossRefGoogle Scholar
  17. 17.
    Carter CL, Allen, Henson DE: Relation of tumor size, lymph node status, and survival in 24740 breast cancer cases. Cancer 1989 (63):181–187PubMedCrossRefGoogle Scholar
  18. 18.
    Müller A, Kubli F, Tschahargane C, Schindler E, Kaufmann M.: Bedeutung der histologischen Aufarbeitung der Axilla beim Staging des invasiven Mammakarzinoms, In: Hermanek P (ed) Bedeutung des TNM-Systems für die klinische Onkologie. Zuckschwerdt, München, Bern, Wien 1986 pp 54–59Google Scholar
  19. 19.
    Moon E, Jones E, Tong T, Serokman R, Bonadonna G, Veronesi U, Vaugussa P, Powles TJ, Buzdar A, Montague E: Development of a natural history data base of breast cancer studies: In: Salmon SE (ed) Adjuvant Therapy of Cancer. Grune &Stratton, Orlando 1987 pp 227–233Google Scholar
  20. 20.
    Kubli F, Müller A, Kaufmann M: Die axilläre Lymphonodektomie in der Therapieplanung beim invasiven Mammakarzinom: In: Hepp H, Scheidel P, Monaghan JM (eds): Lymphonodektomie in der gynakologischen Onkologie. Urban &Schwarzenburg, München, Wien, Baltimore 1988 pp 115–124Google Scholar
  21. 21.
    Rosen P, Lesser M, Kinne D, Beattie E: Discontinous or “skip” metastases in breast cancer: Analysis of 1228 axillary dissections. Ann Surg 1983(197) :276PubMedCrossRefGoogle Scholar
  22. 22.
    Jarasch ED, Nagle R, Kaufmann M, Maurer C, Böcker WJ: Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol 1988 (19):276–289PubMedCrossRefGoogle Scholar
  23. 23.
    Kaufmann M, Feichter GE, Nhila A, Klinga K, Abel U: Flowzytophotometrische Parameter, Hormonrezeptoren und axillärer Lymphknotenstatus als Prognosefaktoren beim primären Mammakarzinom. Geburtsh u Frauenheilk 1988 (48):705–709CrossRefGoogle Scholar
  24. 24.
    Goldhirsch A, Gelber RD, Simes RJ, et al, For the Ludwig Breast Cancer Study Group: Costs and benefits of adjuvant therapy in breast cancer: A quality adjusted survival analysis. J Clin Oncol 1989 (7):36–44PubMedGoogle Scholar
  25. 25.
    Nissen-Meyer R, Host H, Kjellgren K, Mansson B, Norin T: Neoadjuvant chemotherapy in breast cancer: As single perioperative treatment and with supplementary long-term chemotherapy. In: Salmon SE (ed) Adjuvant Therapy of Cancer. Grune &Stratton, Orlando 1987 pp 253–261Google Scholar
  26. 26.
    Senn HJ, Barett-Mahler R, for the OSAKO and SAKK Groups: Update of Swiss adjuvant trials with LMF and CMF in operable breast cancer. In: Salmon SE (ed) Adjuvant Therapy of Cancer. Grune &Stratton, Orlando 1987 pp 243–252Google Scholar
  27. 27.
    Morrison JM, Howell A, Grieve RJ, Monypenny IJ, Walter R, Kelly KA, Waterhouse JA: The West Midlands Oncology Association trials of adjuvant chemotherapy for operable breast cancer. In: Salmon SE (ed) Adjuvant Therapy of Cancer. Grune &Stratton, Orlando 1987 pp 311 -318Google Scholar
  28. 28.
    Jakesz R, Kolb R, Reiner G, Schemper M, Rainer H, Dittrich C, Reiner A: Adjuvant chemotherapy in node-negative breast cancer patients. In: Salmon SE (ed) Adjuvant Therapy of Cancer. Grune &Stratton, Orlando 1987 pp 223–231Google Scholar
  29. 29.
    Scottish Cancer Trials Office: Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Lancet 1987 (ii):171–175Google Scholar
  30. 30.
    Nolvadex Adjuvant Trial Organisation: Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. Br J Cancer 1988(57):608–611CrossRefGoogle Scholar
  31. 31.
    CRC Adjuvant Breast Trial Working Party: Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 1988 (57):604–607CrossRefGoogle Scholar
  32. 32.
    Fornander T, Cedermark B, Mattson A et al: Adjuvant tamoxifen in early breast cancer: Occurence of new primary cancers. Lancet 1989 (i):117–120CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • Manfred Kaufmann
    • 1
  1. 1.Universitäts-FrauenklinikHeidelbergGermany

Personalised recommendations